Sernova Biotherapeutics Inc SVA.TO
TSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 43.97% | 45.35% | 56.59% | 52.66% | 53.71% |
| Total Depreciation and Amortization | -83.34% | -40.17% | -38.75% | -37.86% | -9.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 214.33% | 118.45% | 68.23% | 67.31% | -60.19% |
| Change in Net Operating Assets | -4.10% | -26.10% | -65.48% | -84.52% | -76.13% |
| Cash from Operations | 69.48% | 65.29% | 64.05% | 44.40% | 45.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 314.29% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | 314.29% | -99.51% | -99.73% | -99.78% | -99.96% |
| Total Debt Issued | -67.47% | -62.54% | -- | -- | -- |
| Total Debt Repaid | -2,605.47% | -2,271.67% | 58.22% | 33.23% | 13.14% |
| Issuance of Common Stock | 30.91% | 30.91% | -70.39% | -94.90% | 32,893.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 90.36% | 84.87% | -19.67% | 489.87% | -144.54% |
| Cash from Financing | -54.51% | -52.28% | 22.00% | -2.39% | 3,434.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.83% | 26.80% | 87.18% | -102.35% | 62.93% |